Mesalamine to prevent bowel inflammation after melanoma immunotherapy
Treatments studied
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This study tests whether taking mesalamine can prevent colitis (bowel inflammation) in people with advanced melanoma who are treated with ipilimumab plus nivolumab. It may help reduce dangerous stomach or bowel side effects from this cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have melanoma that cannot be removed with surgery and is stage III or IV.
- You can sign consent and follow the study checkups.
- You are able to do daily activities fairly well (ECOG 0–2).
- You meet basic blood, kidney, and liver lab thresholds (like a minimum white blood cell count, platelets, kidney function, and safe liver enzymes).
- If you could get pregnant, you must have a negative pregnancy test and use very reliable birth control during treatment and for 30 days after; if breastfeeding, you must stop before starting and until 30 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether vedolizumab, a drug that reduces gut inflammation, can prevent diarrhea caused by immunotherapy (a type of cancer treatment). It is for adults with advanced melanoma, lung, or kidney cancer who have a stool marker of inflammation early in treatment.
This trial tests extracorporeal photopheresis (ECP)—a treatment that removes blood, treats it with light, and returns it to your body—to help control severe gut and liver inflammation caused by melanoma immunotherapy drugs that weren't helped by steroids. The goal is to let you continue or restart cancer treatment safely.
This study tests if eating certain prebiotic foods while receiving immunotherapy before melanoma surgery can boost your immune system and improve treatment response. Participants eat study-provided foods and receive standard immunotherapy (ipilimumab with or without nivolumab, or nivolumab with or without relatlimab).
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
This trial tests whether mesalamine, a medicine used for bowel inflammation, can help prevent colorectal cancer in people with Lynch syndrome who do not currently have cancer. It may help by lowering the chance that new pre-cancer growths form over time.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
Hear when a new Immune-related Adverse Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.